By Mike Ward, Global Head of Thought Leadership
Biotechs have fared better in 2020 than companies in many other industries. Despite the disruption caused by the pandemic, biopharma companies have been able to raise record sums of capital, conclude biopartnering deals, launch new medicines, minimize the impact on clinical trial activity, while mobilizing its R&D resources to tackle COVID-19. In our new executive brief we look at the main trends, challenges and drivers of change the biotech industry has faced in 2020.
Download our white paper to learn: